2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
5
Melanoma
4
Carcinoma, Renal Cell
4
Lymphoma, Follicular
3
Lymphoma
3
Sarcoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Carcinoma, Hepatocellular
2
Zollinger-Ellison Syndrome
1
Virus Diseases
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Philadelphia Chromosome
1
Multiple Myeloma
1
Meningeal Carcinomatosis
1
Lymphoproliferative Disorders
1
Lymphomatoid Granulomatosis
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Influenza, Human
1
Hepatitis B, Chronic
1
Hepatitis B
1
Heartburn
1
Gastrointestinal Cancer Metastatic
1
Epstein-Barr Virus Infections
1
Interventions
atezolizumab
2
Gemcitabine
2
Cell Count
2
ziprasidone
1
valrubicin
1
tretazicar
1
pembrolizumab
1
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
enadenotucirev
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Vaccines
1
Tumor Necrosis Factor-alpha
1
Tranexamic Acid
1
Tobramycin
1
Spironolactone
1
Sevelamer
1
Rocuronium
1
Radiotherapy
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Oncolytic Virotherapy
1
Nifedipine
1
Nafcillin
1
Molindone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoviridae Infections
×
Interferons
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled